Boardroom Media

Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Luke Ritchie, Partner & National Head of Retail and Consumer Products at Grant Thornton Australia about the implications of Covid-19 on the Australian discretionary retail market.

Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Tony Markwell, National Managing Partner of Private Advisory at Grant Thornton. They talk about the light at the end of the COVID-19 tunnel, and how we can harness culture and innovation to do things differently in the ‘new normal’.

Grant Thornton is one of the world's leading organisations for independent assurance, tax and advisory. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Madeleine Mattera, National Head of Financial Services at Grant Thornton. They discuss the current COVID-19 crisis and the role of the Financial Services sector in supporting the economy.

Grant Thornton is one of the world's leading organisations of independent assurance, tax and advisory firms. Today Boardroom.Media Reporter Velvet-Belle Templeman speaks to Said Jahani, National Managing Partner - Financial Advisory of Grant Thornton. They discuss COVID-19: how it’s impacting the business world, how various sectors are dealing with the impacts, and how they should be preparing.

Holista CollTech (ASX: HCT) today announced that it has filed its 100%-owned global patent for platform technology that will deliver many fat-soluble medications by creating a water-soluble delivery system. This patented process can apply to a whole range of molecules including the Cannabidiol (CBD) oil industry.

Openpay Group Ltd (OPY) is a payments technology company that offers a buy now, pay later (BNPL) product and is headquartered in Melbourne, Australia. Openpay provides a payments platform that facilitates seamless, secure and swift payments between Customers and Merchants. The Openpay platform allows Customers to make in-store and online purchases, and effectively split the payment for these purchases into multiple repayments over time, while attracting no interest.

Business Journalist Velvet-Belle Templeman speaks to Paul Hopper, the Executive Chairman of SUDA Pharmaceuticals Ltd (ASX: SUD). The company, a leader in oro-mucosal drug delivery, announced that it has entered into a fully-funded feasibility study and option agreement with Spanish pharmaceutical company Laboratorios Ordesa, S.L., (Ordesa). Hopper discusses product commercialisation, exciting developments in their Cancer project, the role of the company's new CEO as well as insights for shareholders in the next 6 months.

Regeneus Ltd (ASX: RGS) a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc (AGC) to terminate their exclusive manufacturing licence and joint venture agreement.

As the U.S. prepares to pass the historic US Farm Bill, which includes the legalisation of industrial hemp, Elixinol Global CEO Paul Benhaim discusses the implications for the business and how the legislation change will support the company’s plans to expand its market operations.

Medlab Clinical Ltd (ASX: MDC) remains uniquely positioned as a fundamentally corner-stoned company in medical research but increasingly delivering a successful path to commercialisation in its Nutraceutical and Cannabis based products.

Medlab Clinical Ltd (ASX: MDC) is pleased to announce the NanoCBD™ update. Medlab’s NanoCBD™ product has been developed out of our US operations, with manufacturing underway at a licenced FDA facility, and has already received its first export order and deposit for 1,500 units to Hong Kong.

Boardroom.Media speaks to Medlab Clinical Limited (ASX:MDC) CEO Sean Hall about Cannabis acting in the world of traditional pharmaceuticals. Medlab is an Australian life science company listed on the Australian Securities Exchange specialising in novel therapeutic discoveries to counter today’s chronic disease and improve quality of life. Medlab stands in the medical and pharmacy community that supports and promotes the health and safety of drug availability on the Australian market.

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company with its principal business goal to produce and supply high quality Cannabinoid based products for the emergent medical markets in Europe, North America and Australasia. The company is built on the vision to be an international pioneer in the biopharmaceutical industry. We discussed the booming Cannabis market and why investors should consider cannabis stocks today.

Boardroom.Media speaks to MMJ Group Holdings Limited (MMJ) director Mike Curtis about the future of the Cannabis market. MMJ Group Holdings Limited owns a portfolio of cannabis sector investments. MMJ aims to invest across the full range of cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D and retail. The legal market in Canada is fully recreational and it is a highly regulated market. MMJ is expecting Australia to be focused in the medicinal market, focusing generally on the clinics. MMJ looks to the higher quality regulated market in terms of not the recreational but really providing quality products to professionals.

MGC Pharmaceuticals Ltd (ASX:MXC) is a European based ‘Seed to Medicine’ bio-pharma company focused on developing and commercialising phytocannabinoid derived medicines, is pleased to announce it has received formal approval for the sale of CannEpil® in Ireland following the recommendation by the Health Products Regulatory Authority (HPRA), CannEpil® is one of MGC Pharma’s Investigational Medicinal Product’s (IMP) to treat drug resistant epilepsy. MGC Pharmaceuticals also announced it has signed a binding term sheet (the ‘Term Sheet’) with established Brazilian business services company, BRASILINVEST Global Business and Development (‘BrasilInvest’) to establish a Joint Venture Company (‘JV Co’) for the dedicated retail sales and marketing of MGC Pharma products into key Brazil and Latin American markets. The JV Co is to be incorporated as a 50% (BrasilInvest)/50% (MGC Pharma) ownership structure.

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company with its principal business goal to produce and supply high quality Cannabinoid based products for the emergent medical markets in Europe, North America and Australasia. The company is built on the vision to be an international pioneer in the biopharmaceutical industry. We discussed the booming Cannabis market and why investors should consider cannabis stocks today.

John Huggart Speaks to Boardroom Media's Will Canty

Boardroom Media's Will Canty speaks with Boardroom Media's John Huggart.

Star Farmer is a company foundered on a propriety platform technology which is a kind of a polymer called a dengrimer.

Chief Commercial Officer Darryl Garber speaks with Boardroom Media about ELMO's cloud based HR software.

Hazer Group Ltd (ASX: HZR) lodges the Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2019. Hazer had a productive quarter as it continued to progress its core development pathways for the Hazer Process of; (i) securing a Commercial Demonstration Plant (“CDP”) to fully demonstrate a working commercial hydrogen production facility based on the Hazer Process, and (ii) supporting Mineral Resources Limited (ASX: MIN) with the commissioning of a graphite focussed pilot plant developed under the Binding Collaboration Agreement between the Companies.